Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium (Q46502489)

22 December 2017

title

Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium (English)

1 reference

22 December 2017

main subject

California

0 references

phase II clinical trial

0 references

metastatic melanoma

1 reference

L-Valinamide, N,N-dimethyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-2-methyl-3-oxo-3-[[(1S)-2-phenyl-1-(2-thiazolyl)ethyl]amino]propyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-

inferred from title

1 reference

inferred from

reverse claim

Dolabella auricularia

1 reference

2

1 reference

22 December 2017

author name string

Margolin K

1

1 reference

22 December 2017

Synold TW

3

1 reference

22 December 2017

Gandara DR

4

1 reference

22 December 2017

Weber J

5

1 reference

22 December 2017

Gonzalez R

6

1 reference

22 December 2017

Johansen MJ

7

1 reference

22 December 2017

Newman R

8

1 reference

22 December 2017

Baratta T

9

1 reference

22 December 2017

Doroshow JH

10

1 reference

22 December 2017

publication date

1 January 2001

1 reference

22 December 2017

Investigational New Drugs

published in

1 reference

22 December 2017

volume

19

1 reference

22 December 2017

page(s)

335-340

1 reference

22 December 2017

issue

4

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1023/a:1010626230081

exact match

0 references

cites work

Identification of a p53-dependent negative response element in the bcl-2 gene

1 reference

12 December 2020

Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification

1 reference

12 December 2020

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

1 reference

12 December 2020

Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

1 reference

12 December 2020

Effects of dolastatins on human B-lymphocytic leukemia cell lines

1 reference

12 December 2020

p53 gene mutation and expression in naevi and melanomas

1 reference

12 December 2020

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

1 reference

12 December 2020

Immunohistochemical detection of p53 in melanomas with rare p53 gene mutations is associated with mdm-2 overexpression

1 reference

12 December 2020

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

1 reference

12 December 2020

Identification of the multidrug-resistance protein (MRP) as the glutathione-S-conjugate export pump of erythrocytes

1 reference

12 December 2020

WAF1, a potential mediator of p53 tumor suppression

1 reference

12 December 2020

Role of P-glycoprotein in dolastatin 10 resistance

1 reference

12 December 2020

Overexpression and mutations of p53 in metastatic malignant melanomas

1 reference

12 December 2020

p53 mutations in human cancers

1 reference

12 December 2020

p53 expression is rare in cutaneous melanomas

1 reference

12 December 2020

Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain

1 reference

12 December 2020

Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors

1 reference

12 December 2020

Quantitation of dolastatin-10 using HPLC/electrospray ionization mass spectrometry: application in a phase I clinical trial

1 reference

12 December 2020

Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.

1 reference

12 December 2020

Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group

1 reference

12 December 2020

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma

1 reference

12 December 2020

Combination of chemotherapy with interleukin-2 and interferon alfa for the treatment of metastatic melanoma.

1 reference

12 December 2020

Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance

1 reference

12 December 2020

Inactivation of Bcl-2 by phosphorylation

1 reference

12 December 2020

Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.

1 reference

12 December 2020

Dolastatin 10 and dolastatin 15: effects of two natural peptides on growth and differentiation of leukemia cells

1 reference

12 December 2020

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

1 reference

12 December 2020

Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway

1 reference

12 December 2020

Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma

1 reference

12 December 2020

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study

1 reference

12 December 2020

Bcl-2: an antidote to programmed cell death

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1010626230081

1 reference

22 December 2017

Dimensions Publication ID

0 references

1 reference

22 December 2017